NSE: NH | BSE: 539551

Mid-range Performer

Download real time

1753.80 -0.20 (-0.01%)

26.01% Fall from 52W High

192.9K NSE+BSE Volume

NSE 29 Aug, 2025 3:31 PM (IST)

35,840.8

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Narayana Hrudayalaya Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NH, BSE:539551 Narayana Hrudayalaya Ltd.

Narayana Hrudayalaya Ltd.

07 Aug 2018

1753.80

-0.01%

Narayana Hrudayalaya

Buy: Narayana Hrudayalaya Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 25.2% YoY to | 652.3 crore (I-direct estimate: | 609.4 crore) mainly due to consolidation of Health City Cayman Islands Ltd (Cayman) and incremental revenues from new hospitals EBITDA margins declined 240 bps YoY to 7.3% (I-direct estimate: 8.3%) mainly due to higher employee expenses. EBITDA de-grew 5.9% YoY to | 47.4 crore (I-direct estimate: | 50.4 crore) Net loss was at | 4.1 crore (I-direct estimate of net profit: | 5.8 crore)...

Narayana Hrudayalaya Ltd. is trading above its 200 day SMA of 1618.3

Narayana Hrudayalaya Ltd.

31 May 2018, 12:00AM

1753.80

-0.01%

Narayana Hrudayalaya

Buy: Narayana Hrudayalaya Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 34% YoY to | 647 crore (I-direct estimate: | 595 crore) mainly due to consolidation of Health City Cayman Islands (Cayman) and incremental revenues from new hospitals EBITDA margins declined 398 bps YoY to 8.1% (I-direct estimate: 12.0%) mainly due to an increase in doctor payouts, expenses related to new facilities, GST implementation besides losses related to stent and implants regulation. EBITDA de-grew 10.3% YoY to | 52...

Narayana Hrudayalaya Ltd. is trading below its 30 day SMA of 1866.9

Narayana Hrudayalaya Ltd.

07 Feb 2018

1753.80

-0.01%

Result Update:Narayana Hrudaya

Buy: Narayana Hrudayalaya Ltd.

Target

Axis Direct

Q3 revenue was up 22% YoY on strong volume growth, but EBITDA slipped 2% YoY on (1) EBITDA loss of ~Rs 70 mn at its recently-commissioned children's hospital in Mumbai and (2) investments on talent acquisition especially at its new hospitals.

Number of FII/FPI investors increased from 277 to 335 in Jun 2025 qtr.

Narayana Hrudayalaya Ltd.

05 Feb 2018

1753.80

-0.01%

Narayana Hrudayalaya

Buy: Narayana Hrudayalaya Ltd.

ICICI Securities Limited

Revenues grew 22% YoY to | 554 crore mainly due to an improvement in ARPOB and occupancy rates. However, revenues were below I-direct estimate of | 587 crore mainly due to lower-thanexpected ARPOB (80 lakh vs. I-direct estimate of 84.8 lakh) and lower...

Narayana Hrudayalaya Ltd. is trading below its 30 day SMA of 1866.9

Narayana Hrudayalaya Ltd.

26 Dec 2017

1753.80

-0.01%

Narayana Hrudayalaya

Buy: Narayana Hrudayalaya Ltd.

Target

ICICI Securities Limited

Blended model of affordable + high-quality services Narayana Hrudayalaya (NHL) has a legacy model based on affordability over the years. Due to strict control over costs and capital, the company was making reasonable profits. However, as it looks to scale up in other regions, where the consideration for quality has more weight than affordability, the model is likely to be modified from 'affordable'' to a mix of affordable + quality at premium. Cases in point are the recent acquisition of Gurugram hospital and buying out of partner in the Cayman...

Narayana Hrudayalaya Ltd. has gained 38.21% in the last 1 Year

Narayana Hrudayalaya Ltd.

08 Dec 2017

1753.80

-0.01%

Narayana Hrudayalaya

Buy: Narayana Hrudayalaya Ltd.

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research We met the management of Narayana Hrudayalaya (NHL) to understand its business model and future prospects. NHL was founded by cardiac surgeon Dr Devi Prasad Shetty in 2000. The company operates as a chain of multispecialty, tertiary and primary healthcare facilities. NHL has a strong legacy in cardiac and renal sciences. Cardiac sciences alone contributed 42% to FY17 sales. The company has a strong presence in Karnataka and Eastern India. NHL is also growing in western and central India. The...

Narayana Hrudayalaya Ltd. is trading below its 30 day SMA of 1866.9

Narayana Hrudayalaya Ltd.

10 Nov 2017

1753.80

-0.01%

Result Update:Narayana Hrudaya

Buy: Narayana Hrudayalaya Ltd.

Target

Axis Direct

While Narayana Hrudayalaya's (NH) Q2FY18 revenue was up 15% YoY, EBITDA slip (8% YoY decline) can largely be attributed to (1) EBITDA loss of ~Rs 80 mn at its recently-commissioned children's hospital in Mumbai and (2) Price control on cardiac stents which impacted profitability by ~Rs 70 mn.

Geojit BNP Paribas decreased Sell price target of Narayana Hrudayalaya Ltd. to 1642.0 on 20 Aug, 2025.

Narayana Hrudayalaya Ltd.

09 Aug 2017

1753.80

-0.01%

Result Update - Narayana Hrudayalaya

Buy: Narayana Hrudayalaya Ltd.

Target

Axis Direct

Blip in Narayana Hrudayalayas (NH) Q1FY18 financials can largely to attributed to (1) Price control on cardiac stents (cardiac contributes 44% to revenue) which impacted profitability by ~Rs 100 mn and (2) EBITDA loss of ~Rs 70 mn at its recently-commissioned childrens hospital in Mumbai.

Number of FII/FPI investors increased from 277 to 335 in Jun 2025 qtr.

Narayana Hrudayalaya Ltd.

07 Jun 2017

1753.80

-0.01%

Result Update:Narayana Hrudaya

Buy: Narayana Hrudayalaya Ltd.

Recommendation Target

Axis Direct

Narayana Hrudayalaya's (NH) growth momentum continued in FY17 with 30% YoY growth in EBITDA to Rs 2.3 bn (in line).We believe NH is entering a strong growth phase (~20% revenue CAGR over FY17-20), as it continues to pursue an asset light expansion coupled with higher capacity utilization.

Narayana Hrudayalaya Ltd. is trading above its 200 day SMA of 1618.3

Narayana Hrudayalaya Ltd.

08 Feb 2017

1753.80

-0.01%

Result Update:Narayana Hrudaya

Hold: Narayana Hrudayalaya Ltd.

Axis Direct

In a seasonally tepid quarter, Narayana Hrudayalaya's (NH) growth momentum was hurt by demonetization (~60% of NH's revenue is from walk-in patients).

Geojit BNP Paribas decreased Sell price target of Narayana Hrudayalaya Ltd. to 1642.0 on 20 Aug, 2025.

Is Narayana Hrudayalaya Ltd. worth buying?

216 Votes:

Buy 80.56%

Sell 14.81%

Hold 4.63%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf